75 related articles for article (PubMed ID: 21118387)
21. Clinical performance of JAK2 V617F mutation detection assays in a molecular diagnostics laboratory: evaluation of screening and quantitation methods.
Cankovic M; Whiteley L; Hawley RC; Zarbo RJ; Chitale D
Am J Clin Pathol; 2009 Nov; 132(5):713-21. PubMed ID: 19846812
[TBL] [Abstract][Full Text] [Related]
22. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.
Larsen TS; Christensen JH; Hasselbalch HC; Pallisgaard N
Br J Haematol; 2007 Mar; 136(5):745-51. PubMed ID: 17313377
[TBL] [Abstract][Full Text] [Related]
23. Molecular insights into the morphology of myeloproliferative neoplasms using an in situ PCR assay specific for the JAK2 mutation V617F.
Gattenlohner S; Serfling E; Einsele H; Müller-Hermelink HK
Leukemia; 2009 Jan; 23(1):196-9. PubMed ID: 18580953
[No Abstract] [Full Text] [Related]
24. Comparison of JAK2 V617F burden quantitation by two different quantitative-polymerase chain reaction methods.
Le Bars H; Boulland ML; Bareau B; Grosbois B; Corolleur M; Lamy T; Fardel O
Int J Lab Hematol; 2010 Aug; 32(4):458-60. PubMed ID: 20331762
[No Abstract] [Full Text] [Related]
25. Janus kinase 2 V617F mutation is detectable in spleen of patients with chronic myeloproliferative diseases suggesting a malignant nature of splenic extramedullary hematopoiesis.
Konoplev S; Hsieh PP; Chang CC; Medeiros LJ; Lin P
Hum Pathol; 2007 Dec; 38(12):1760-3. PubMed ID: 17707884
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation.
Ammatuna E; Ottone T; Zaza S; Lavorgna S; Grillo R; Curzi P; Panetta P; Federici G; Amadori S; Lo-Coco F
Ann Hematol; 2007 May; 86(5):355-61. PubMed ID: 17285276
[TBL] [Abstract][Full Text] [Related]
27. A new potential oncogenic mutation in the FERM domain of JAK2 in BCR/ABL1-negative and V617F-negative chronic myeloproliferative neoplasms revealed by a comprehensive screening of 17 tyrosine kinase coding genes.
Aranaz P; Ormazábal C; Hurtado C; Erquiaga I; Calasanz MJ; García-Delgado M; Novo FJ; Vizmanos JL
Cancer Genet Cytogenet; 2010 May; 199(1):1-8. PubMed ID: 20417861
[TBL] [Abstract][Full Text] [Related]
28. JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.
Toyama K; Karasawa M; Yamane A; Irisawa H; Yokohama A; Saitoh T; Handa H; Matsushima T; Sawamura M; Miyawaki S; Murakami H; Nojima Y; Tsukamoto N
Br J Haematol; 2007 Oct; 139(1):64-9. PubMed ID: 17854308
[TBL] [Abstract][Full Text] [Related]
29. Design and evaluation of a real-time PCR assay for quantification of JAK2 V617F and wild-type JAK2 transcript levels in the clinical laboratory.
Merker JD; Jones CD; Oh ST; Schrijver I; Gotlib J; Zehnder JL
J Mol Diagn; 2010 Jan; 12(1):58-64. PubMed ID: 19959796
[TBL] [Abstract][Full Text] [Related]
30. JAK2 V617F mutation can be reliably detected in serum using droplet digital PCR.
Nystrand CF; Ghanima W; Waage A; Jonassen CM
Int J Lab Hematol; 2018 Apr; 40(2):181-186. PubMed ID: 29150911
[TBL] [Abstract][Full Text] [Related]
31. Comparison of whole blood vs purified blood granulocytes for the detection and quantitation of JAK2(V617F).
Hermouet S; Dobo I; Lippert E; Boursier MC; Ergand L; Perrault-Hu F; Pineau D
Leukemia; 2007 May; 21(5):1128-30. PubMed ID: 17301814
[No Abstract] [Full Text] [Related]
32. MassARRAY assay: a more accurate method for JAK2V617F mutation detection in Chinese patients with myeloproliferative disorders.
Fu JF; Shi JY; Zhao WL; Li G; Pan Q; Li JM; Hu J; Shen ZX; Jin J; Chen FY; Chen SJ
Leukemia; 2008 Mar; 22(3):660-3. PubMed ID: 17728780
[No Abstract] [Full Text] [Related]
33. JAK2 V617F "indeterminate" results by MutaScreen can be easily resolved using MutaQuant kits.
Hoteit RM; Shammaa DM; Mahfouz RA
Genet Test Mol Biomarkers; 2012 Feb; 16(2):146-9. PubMed ID: 21933004
[TBL] [Abstract][Full Text] [Related]
34. No evidence for amplification of V617F JAK2 in myeloproliferative disorders.
Jones AV; Bunyan DJ; Cross NC
Leukemia; 2007 Dec; 21(12):2561-3. PubMed ID: 17611555
[No Abstract] [Full Text] [Related]
35. Is the JAK2(V617F) mutation detectable in healthy volunteers?
Martinaud C; Brisou P; Mozziconacci MJ
Am J Hematol; 2010 Apr; 85(4):287-8. PubMed ID: 20162546
[No Abstract] [Full Text] [Related]
36. Recurrent refractory arterial thromboembolism associated with the Janus kinase 2 V617F mutation.
Ali FR; Roberts LN; Mistry H; Patel RK; Edmondson RA; Arya R
J Vasc Surg; 2009 Jan; 49(1):211-3. PubMed ID: 19174256
[TBL] [Abstract][Full Text] [Related]
37. Development and validation of a tetra-primer amplification refractory mutation system-polymerase chain reaction combined with melting analysis-assay for clinical JAK2 V617F mutation detection.
Liu W; Hu T; Chen Y; Zhang X; Gu X; Guan M
Mol Diagn Ther; 2014 Oct; 18(5):579-85. PubMed ID: 25015634
[TBL] [Abstract][Full Text] [Related]
38. Referral centre variation in requesting JAK2 V617F mutation analysis for the investigation of a myeloproliferative neoplasm.
Langabeer SE
J Clin Pathol; 2012 Dec; 65(12):1149-50. PubMed ID: 22872706
[No Abstract] [Full Text] [Related]
39. The JAK2 V617F mutation is detectable in granulocyte populations at greater than two copies per cell among individuals with myeloproliferative disorders.
Hammond E; Shaw K; Herrmann R
Leukemia; 2007 Apr; 21(4):815-6; discussion 816-8. PubMed ID: 17268517
[No Abstract] [Full Text] [Related]
40. JAK2: implications for diagnosis and classification of myeloproliferative disorders.
Campbell P
Lijec Vjesn; 2007 May; 129 Suppl 3():30-2. PubMed ID: 18959057
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
